NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy

Nicholas Hardcastle 1,7*, Michael S. Hofman 2, Ching-Yu Lee 1, Jason Callahan 2, Lisa Selbie 3, Farshad Foroudi 4, Mark Shaw 3, Sarat Chander 3, Andrew Lim 5, Brent Chesson 5, Declan G. Murphy 6,8, Tomas Kron 1,7,8 and Shankar Siva 3,8

Abstract

Introduction: In prostate cancer patients, imaging of bone metastases is enhanced through the use of sodium fluoride positron emission tomography (18F-NaF PET/CT). This imaging technique shows areas of enhanced osteoblastic activity and blood flow. In this work, 18F-NaF PET/CT was investigated for response assessment to single fraction stereotactic ablative body radiotherapy (SABR) to bone metastases in prostate cancer patients.

Methods: Patients with bone metastases in a prospective trial treated with single fraction SABR received a 18F-NaF PET/CT scan prior to and 6 months post-SABR. The SUV_{max} in the tumour was determined and the difference between before and after SABR determined. The change in uptake in the non-tumour bone was also measured as a function of the received SABR dose.

Results: Reduction in SUV_{max} was observed in 29 of 33 lesions 6 months after SABR (mean absolute decrease in SUV_{max} 17.7, 95% CI 25.8 to −9.4, \(p = 0.0001\)). Of the three lesions with increased SUV_{max} post-SABR, two were from the same patient and located in the vertebral column. Both were determined to be local progression in addition to one fracture. The third lesion (in a rib) was shown to be controlled locally but suffered from a fracture at 24 months. Progression adjacent to the treated volume was observed in two patients. The non-tumour bone irradiated showed increased loss in uptake with increasing dose, with a median loss in uptake of 23.3% for bone receiving 24 Gy.

Conclusion: 18F-NaF PET/CT for response assessment of bone metastases to single fraction SABR indicates high rates of reduction of osteoblastic activity in the tumour and non-tumour bone receiving high doses. The occurrence of marginal recurrence indicates use of larger clinical target volumes may be warranted in treatment of bone metastases.

Trial registration: POPSTAR, ‘Pilot Study of patients with Oligometastases from Prostate cancer treated with STereotactic Ablative Radiotherapy’, Universal Trial Number U1111-1140-7563, Registered 17th April 2013.

Keywords: Prostate cancer, Metastases, SABR, Imaging, PET, NaF
Background
Prostate cancer represents a major cancer burden in men, representing the most common male cancer diagnosis [1]. Prostate cancer staging determines appropriate treatment at initial presentation and during disease progression and makes use of various medical imaging techniques. The most probable site of distant metastases in prostate cancer is bone, thus imaging techniques used for visualization of prostate metastases must be able to accurately visualize sites of bone disease [2]. This is particularly so with increasing interest in metastasis-directed therapy (MDT) for oligometastatic prostate cancer [3–5]. The standard imaging for determination of prostate cancer bone metastases has been whole body bone scan with 2D scintigraphy or single photon emission computed tomography (SPECT) approaches, using 99mTc methylene diphosphonate [6, 7]. These tracers are taken up at sites of high osteoblastic activity representing bone turnover. The tumour burden as represented on bone scans can be quantified into a bone scan index ing bone turnover. The tumour burden as represented taken up at sites of high osteoblastic activity represent-

apy (SABR). In this study we examine 18F-NaF uptake prior for local MDT such as stereotactic ablative body radiother-

imaging of skeletal metastases which may be suitable for geometric uncertainties in the treatment. In the case of vertebral metastases, a clinical target volume (CTV) was contoured as visualised on the 18F-NaF PET and planning CT imaging, limited to bone. For non-vertebral metastases, an isotropic 5 mm planning target volume (PTV) margin was applied to the GTV to account for geometric uncertainties in the treatment. In the case of vertebral metastases, a clinical target volume (CTV) was applied according to the International Spine Radiosurgery Consortium consensus guidelines [18]. A 2–3 mm PTV margin was then applied to the CTV. Treatment planning was performed in the Eclipse treatment planning system (v11, Varian Medical Systems, Palo Alto, USA). Non-vertebral targets were treated with 3D conformal treatment plans which consisted of 7–9 beams typically including 1–2 non-coplanar beams. Dose was prescribed such that at least 99% of the PTV received 20 Gy, with a maximum dose between 125 and 140%. Vertebral targets were treated with a 9–12 coplanar IMRT fields, and prescribed such that at least 80% of the PTV received 18 Gy, with a maximum dose between 125 and 140%. Dose was calculated with the AAA algorithm at 2.5 mm resolution for non-vertebral targets and 1.5 mm resolution for vertebral targets. Radiotherapy was delivered on a Varian 21iX or Varian TrueBeam STx linear accelerator. Patients were immobilised in a vacuum immobilisation bag. Image guidance was performed using cone-beam CT (CBCT) and/or Exactrac planar x-ray imaging with a 0 mm tolerance for shifts. Mid-treatment CBCT was performed to ensure patient setup accuracy during treatment.

Image response assessment
The pre-treatment and post-treatment 18F-NaF PET/CT scans and the radiotherapy planning CT scan with

Methods
This is a pre-specified exploratory analysis of a prospective clinical trial (POPSTAR, ‘Pilot Study of patients with Oligometastases from Prostate cancer treated with STereotactic Ablative Radiotherapy’, Universal Trial Number U1111–1140–7563) [17]. Between April 2013 and November 2014 33 patients with oligometastatic prostate cancer were enrolled with written informed consent. They received a single fraction of 20 Gy to a total of 50 metastases. All lesions in a given patient were treated synchronously within in a single treatment course. All patients had a 18F-NaF PET/CT at screening, and 6 months post-treatment. Patients were excluded from the study if they had more than three metastases after PET/CT screening. The Quality of Life including pain scores, and disease progression for the whole cohort has previ-

ously been reported [17]. The current analysis is limited to those patients with demonstrable bone metastases who received the treatment protocol.

3 MBq/kg of 18F-NaF was administered by intravenous injection followed by a 60 min uptake period. A low-dose CT acquisition was obtained first followed by the PET acquisition. Patients were imaged from vertex to toes on a PET/CT scanner (Discovery 690 GE Healthcare, USA). No fasting was required. Patients were encouraged to void prior to imaging.

Radiotherapy simulation CT was performed less than 2 weeks prior to radiotherapy treatment. Scans were performed on a Philips Brilliance Big Bore CT scanner with a 2 mm slice thickness at 140 kV. The gross tumour volume (GTV) was contoured as visualised on the 18F-NaF PET and planning CT imaging, limited to bone. For non-vertebral metastases, an isotropic 5 mm planning target volume (PTV) margin was applied to the GTV to account for geometric uncertainties in the treatment. In the case of vertebral metastases, a clinical target volume (CTV) was applied according to the International Spine Radiosurgery Consortium consensus guidelines [18]. A 2–3 mm PTV margin was then applied to the CTV. Treatment planning was performed in the Eclipse treatment planning system (v11, Varian Medical Systems, Palo Alto, USA). Non-vertebral targets were treated with 3D conformal treatment plans which consisted of 7–9 beams typically including 1–2 non-coplanar beams. Dose was prescribed such that at least 99% of the PTV received 20 Gy, with a maximum dose between 125 and 140%. Vertebral targets were treated with a 9–12 coplanar IMRT fields, and prescribed such that at least 80% of the PTV received 18 Gy, with a maximum dose between 125 and 140%. Dose was calculated with the AAA algorithm at 2.5 mm resolution for non-vertebral targets and 1.5 mm resolution for vertebral targets. Radiotherapy was delivered on a Varian 21iX or Varian TrueBeam STx linear accelerator. Patients were immobilised in a vacuum immobilisation bag. Image guidance was performed using cone-beam CT (CBCT) and/or Exactrac planar x-ray imaging with a 0 mm tolerance for shifts. Mid-treatment CBCT was performed to ensure patient setup accuracy during treatment.

Image response assessment
The pre-treatment and post-treatment 18F-NaF PET/CT scans and the radiotherapy planning CT scan with
contours and dose grid were imported into MIM software (v6.6, MIM software, Cleveland, USA). The CT components of the $^{18}$F-NaF PET/CT scans were registered to the planning CT scan. An initial rigid registration was performed on the whole CT data set. This was further refined by rigid registration using a bounding box approximately $5 \times 5 \times 5$ cm surrounding the GTV. This was manually adjusted if required to ensure accurate registration at the bone target. This rigid registration was then applied to the PET component of the $^{18}$F-NaF PET/CT scan.

**Tumour response**
The SUV$_{\text{max}}$ was determined for the GTV contour from the pre- and post-treatment $^{18}$F-NaF PET data. The difference in SUV$_{\text{max}}$ from pre- to post-treatment was calculated as a percentage of the pre-treatment SUV$_{\text{max}}$.

**Normal bone response**
The bone was contoured on the axial slices from 2 cm above to 2 cm below the PTV using a threshold of 120 HU followed by manual correction. An isotropic 2 cm margin was applied to the PTV and the intersection of this and the bone contour was derived to result in a proximal bone (bone within 2 cm of the target). This ensured the bone contour included only the bone that was accurately registered between the three scans. The GTV was subtracted from the proximal bone contour to obtain proximal non-tumour bone. The radiotherapy isodose lines at 2 Gy intervals were converted into contours. These were subtracted from each other, and Boolean intersection with the proximal non-tumour bone was performed to result in contours covering proximal non-tumour bone receiving each 2 Gy dose interval up to 24 Gy. The mean, median, maximum and standard deviation in non-tumour bone receiving each dose interval was extracted. The change in mean SUV after SABR was computed for proximal bone receiving each of the dose levels as $\frac{\text{SUV}_{\text{post}} - \text{SUV}_{\text{pre}}}{\text{SUV}_{\text{pre}}}$. The change in SUV$_{\text{mean}}$ in the non-tumour bone was reviewed for all patients with bone fractures post treatment (CTCAE v4.0).

**Results**
Twenty-one patients from the patient population with bone metastases were included in this analysis. A total of 33 bone lesions were irradiated (Additional file 1: Table S1). The baseline SUV characteristics of the lesions is shown in Additional file 2: Table S2. The mean (± 1 st. dev.) time of post-therapy PET was 7.4 ± 1.0 months. The SUV$_{\text{mean}}$ of normal, un-irradiated bone was consistent between pre and post-treatment scans, with a mean ratio, post/pre of 0.98 ± 0.08. In this cohort, $^{18}$F-NaF had detected an additional 14 metastases, over that detected with CT and bone scan.

**SUV$_{\text{max}}$ differences in tumour**
The SUV$_{\text{max}}$ was computed in the GTV contour on pre and post treatment $^{18}$F-NaF PET scans. Figure 1 shows for an example patient the maximum intensity projection of the pre and post-SABR $^{18}$F-NaF PET images with the planned isodose lines. Figure 2 shows a waterfall plot of the relative change in SUV$_{\text{max}}$ after SABR. Reduction in tumour SUV$_{\text{max}}$ was observed in 29/33 lesions. The mean absolute decrease in SUV$_{\text{max}}$ after SABR was 17.7 (95% CI – 25.8 to – 9.4, $p = 0.0001$). Increase in SUV$_{\text{max}}$ at 6 months was observed in three of 33 lesions treated with SABR; of these, two were from the same patient. Figure 3 shows the three lesions with increased SUV$_{\text{max}}$. Patient 18 had T4 and L2 lesions that were determined to be a local progression based on follow up with CT and PSMA PET imaging at 20 months post treatment. Specifically for the T4 lesion, full coverage of the GTV with the prescription dose was not achieved due to the
proximity of the spinal cord, which was a dose-limiting structure. In addition, a grade 3 fracture was also observed at 18 months post treatment at L2. In the case of a right rib lesion in patient 3, local control based on repeat CT and PSMA PET was achieved; however a grade 2 fracture was observed at 24 months post SABR.

Non-tumour bone
The change in $SUV_{\text{mean}}$ in the non-GTV bone receiving each dose level from 0 Gy to 24 Gy was computed. Figure 4 shows the average change in $SUV_{\text{mean}}$ for the non-tumour bone surrounding 33 targets as a function of dose. The mean percentage reduction in the non-tumour bone

![Waterfall plot of the change in SUVmax of the GTV after SABR and (b) absolute SUVmax before and after SABR](image)

Fig. 2 a Waterfall plot of the change in SUVmax of the GTV after SABR and (b) absolute SUV$_{\text{max}}$ before and after SABR

![Pre and post-treatment NaF scans for the two patients (three lesions) with increased SUV$_{\text{max}}$ in the tumour. The tumour is shown by the green contour, the PTV in blue and the volume receiving 20 Gy in orange. The spinal cord is shown in yellow for Patient 18](image)

Fig. 3 Pre and post-treatment NaF scans for the two patients (three lesions) with increased SUV$_{\text{max}}$ in the tumour. The tumour is shown by the green contour, the PTV in blue and the volume receiving 20 Gy in orange. The spinal cord is shown in yellow for Patient 18
reduced with increasing dose, with a mean reduction of 23.3% for non-tumour bone receiving 24 Gy. Figure 5 shows a representative patient (Patient 10) treated for a right ilium metastasis. Reduction in the tumour uptake is observed, as is reduction in the surrounding bone uptake in particular at the 16–20 Gy dose range.

In three patients, markedly higher $^{18}$F-NaF uptake in the low dose area of non-tumour bone was observed. In Patient 6, although there was significant reduction in uptake in the treated area, increased uptake in the contiguous bone immediately adjacent to the treated volume was observed. Similarly for Patient 4, increased uptake was observed post-treatment immediately adjacent to the treated volume. These were both determined to be marginal recurrence. The pre and post-treatment scans for these two patients are shown in Fig. 6. The third patient with increase in SUV adjacent to the treated volume (Patient 18, R Acetabulum), had subsequent CT imaging which showed stable morphology and PSMA PET negativity.

Two patients had grade 2 fractures (Patient 3: Right Rib and Patient 20: Left Rib) and one patient had a grade 3 fracture (Patient 18, L2 Vertebra). The lesions for Patient 3 and Patient 18 did not show response to treatment at 6 months on the $^{18}$F-NaF.

Discussion
The POPSTAR trial was a prospective evaluation of SABR for oligometastases from prostate cancer and involved high, single fraction doses to bone and lymph node metastases [17]. This is the first study to demonstrate $^{18}$F-NaF as a response assessment tool in the context of SABR to bone metastases. $^{18}$F-NaF provides high spatial resolution and high sensitivity/specificity.

![Fig. 4 Mean change in SUV_{mean} in non-GTV bone for the population of patients. The uncertainty bars represent ±1 standard deviation](image-url)

![Fig. 5 Pre and post-treatment images for Patient 10, Rt Ilium. GTV is shown in red, and isodose lines in 2 Gy increments from 4 Gy to 20 Gy are shown various colours. Reduction in the tumour uptake post-treatment is observed, as well as reduction in the non-tumour bone irradiated in particular in the 16–20 Gy region](image-url)
measurement of bone metastases and is representative of osteoblastic activity and blood flow. In the current study we have demonstrated that a single high dose fraction of external beam radiotherapy reduces $^{18}$F-NaF uptake in bone at 6 months, thus can be considered to reduce osteoblastic activity in bone metastases in the majority of patients. We have also shown a reduction of osteoblastic activity in regions of non-tumour bone treated to high doses per fraction. Bone fracture remains a side effect in SABR to bone lesions, with two Grade 2 and one Grade 3 fractures observed in the POPSTAR trial. In all the patients that had bone fracture post-SABR, there was high residual NaF uptake within the treated field, or there was new uptake adjacent to the treated volume as visualised on the follow up $^{18}$F-NaF PET scan. As reported previously for this cohort, for the bone metastasis-specific Quality of Life module (EORTC QLQ-BM22), painful sites, pain characteristics, and functional interference increased from baseline only at the 24-mo timepoint [17].

In the POPSTAR trial, bone metastasis was defined using a combination of CT and $^{18}$F-NaF scan information. The primary tumour was delineated by an experienced radiation oncologist and a 5 mm margin was applied to account for geometric uncertainty in the treatment delivery (planning target volume, [PTV]). In the subset of vertebral tumours, a CTV was applied according to international consensus guidelines, with a 2 mm CTV-PTV expansion. The use of $^{18}$F-NaF PET in the current study however has shown the potential inadequacy of direct expansion to PTV in non-vertebral bone without a CTV margin. Three patients had regions of increased uptake immediately adjacent to the treated volume, suggesting marginal failure. This may be mitigated by the use of a CTV margin for all bone metastases, similar to the international consensus guidelines for spine metastases. Despite the inclusion of a CTV in vertebral targets, there are still limitations with full coverage of the GTV due to the close proximity of dose limiting structures such as the spinal cord.

In more recent years, $^{18}$F-Fluoromethylcholine has been used for directing SABR to prostate cancer metastases, with some prognostic value [19]. Prostate specific membrane antigen (PSMA) PET scanning has however become the scanning modality of choice for prostate cancer in the metastatic setting [20]. PSMA PET has been shown to have comparable sensitivity and specificity as $^{18}$F-NaF PET for bone metastases in one study [21], however Uprimny et al. [22] found $^{18}$F-NaF PET detected more skeletal metastases and had a higher tumour to background ratio than PSMA PET. PSMA PET has the additional advantage of visualising soft-tissue metastases, however is limited to prostate cancer and renal cell carcinoma [23]. $^{18}$F-NaF PET thus has a role in response assessment for skeletal metastases in both prostate and non-prostate cancer.
Conclusion
In this study we have shown the response to a high dose single fraction SABR treatment to prostate bone oligometastases as visualised on 18F-NaF PET/CT. In the majority of patients, SABR reduces 18F-NaF PET/CT uptake in the tumour, and in high dose regions reduces uptake in non-tumour bone. Regions of increased uptake immediately adjacent to treated volumes suggest that increased clinical target volumes are required in the treatment of bone metastases with SABR.

Additional files

Additional file 1: Table S1. Baseline characteristics of the patients included in this study. These are only the patients that had bone metastases. (DOCX 27 kb)

Additional file 2: Table S2. Individual lesion characteristics. Non-contiguous patient numbering is used as we are describing the bone metastases only, rather than all metastases treated in this clinical trial. (DOCX 17 kb)

Acknowledgements
The Prostate Cancer Foundation of Australia and the Movember Foundation provided funding for the study.

Authors’ contributions
All authors contributed to manuscript preparation. NH contributed to study design, performed data and statistical analysis and manuscript writing; MSH contributed to study design, performed clinical reporting and data interpretation; CYL performed data analysis; JC performed data interpretation, image acquisition; LS performed data collection; FF, MS, SC performed clinical interpretation and patient recruitment; AL and BC performed treatment planning; DGM performed clinical interpretation; TR provided input on data collection and analysis; SS contributed to study design, was trial PI and contributed to data analysis and interpretation. All authors read and approved the final manuscript.

Funding
The Prostate Cancer Foundation of Australia and the Movember Foundation provided funding for the study. MSH and SS are supported by Clinical Fellowship Awards from the Peter MacCallum Foundation.

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to consent not obtained to make data public, but are available from the corresponding author on reasonable request, and subject to ethics approval.

Ethics approval and consent to participate
This prospective intervention clinical trial was approved by the Peter MacCallum Cancer Centre institutional review board, Melbourne, Australia (POPSTAR, Pilot Study of patients with Oligometastases from Prostate cancer treated with Stereotactic Ablative Radiotherapy, Universal Trial Number U1111–1140-7563); All patients signed informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. 2Division of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. 3Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. 4Olivia Newton-John Cancer & Wellness Centre | Austin Health, 145 Studley Road, PO Box 5555, Heidelberg 3084, Australia. 5Department of Radiation Therapy, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. 6Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. 7Centre for Medical Radiation Physics, University of Wollongong, Wollongong, NSW 2522, Australia. 8Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3000, Australia.

Received: 17 April 2019 Accepted: 16 August 2019
Published online: 05 September 2019

References
1. Kelly SP, Anderson WF, Rosenberg PS, Cook MB. Past, current, and future incidence rates and burden of metastatic prostate Cancer in the United States. Eur Urol Focus. 2018;4(1):121–7. https://doi.org/10.1016/j.euf.2017.10.014.
2. Mazzone E, Preisser F, Nazzani S, et al. Location of metastases in contemporary prostate Cancer patients affects Cancer-specific mortality. Clin Genitourin Cancer. 2018;16(5):375–384.e1. https://doi.org/10.1016/j.clgc.2018.05.016.
3. Muldemans JL, Romak LB, Kwon ED, Park SS, Olivier KR. Stereotactic body radiation therapy for Oligometastatic prostate Cancer. Int J Radiat Oncol Biol Phys. 2016;95(2):696–702. https://doi.org/10.1016/j.ijrobp.2016.01.032.
4. Suteru P, Clump DA, Kalsch R, et al. Initial results of a multicenter phase 2 trial of stereotactic ablative radiation therapy for Oligometastatic Cancer. Int J Radiat Oncol Biol Phys. 2019;103(1):116–22. https://doi.org/10.1016/j.ijrobp.2018.08.027.
5. Bridget Koonz BF, Editor A. Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer: The Hunt for the Silver Bullet. doi:https://doi.org/10.1016/j.ijrobp.2017.05.020.
6. Iagaru A, Mittra E, Dick DW, Gambhir SS. Prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, and 18F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14(2):252–9. https://doi.org/10.1007/s11047-011-0486-2.
7. Jambor I, Kuisima A, Ramadan S, et al. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT,18F-NaF PET/CT and whole body 1.5T MRI including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol (Mad). 2016;55(1):59–67. https://doi.org/10.3109/02841075.2015.1027411.
8. Miyoshi Y, Uemura K, Kawahara T, et al. Prognostic value of automated bone scan index in men with metastatic castration-resistant prostate Cancer treated with enzalutamide or Abiraterone acetate. Clin Genitourin Cancer. 2017;15(4):472–8. https://doi.org/10.1016/j.clgc.2016.12.020.
9. Wakabayashi H, Nakajima K, Mizokami A, et al. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases. Ann Nucl Med. 2013;27(9):802–7. https://doi.org/10.1007/s12149-013-0749-z.
10. Even-Sapir E, Metser U, Mishani E, Lievishitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47(2):287–97. doi:10.2287/287.
11. Schirmeister H, Glattig G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scan, SPECT, and (18) F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42(12):1800–4 http://www.ncbi.nlm.nih.gov/pubmed/11752076. Accessed 21 Aug 2018.
12. Blau M, Ganatra R, Bender MA. 18 F-fluoride for bone imaging. Semin Nucl Med. 1972;2(1):31–7 http://www.ncbi.nlm.nih.gov/pubmed/5059349. Accessed 6 Dec 2018.
13. Grant FD, Fehy FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2007;48(1):68–78. https://doi.org/10.2967/jnumed.106.037200.
14. Even-Sapir E, Metser U, Flusser G, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45(2):272–8.
15. Hicks RJ, Hofman MS. Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat Rev Clin Oncol. 2012;9(12):712–20. https://doi.org/10.1038/ nrclonc2012.188.
16. Anvola S, Jambor I, Kuisima A, et al. Comparison of standardized uptake values between 99m Tc-HDP SPECT/CT and 18 F-NaF PET/CT in bone metastases of breast and prostate cancer. Eur J Nucl Med Mol Imaging Res. 2019(1). https://doi.org/10.1186/s13550-019-0475-z.
17. Siva S, Bressel M, Murphy DG, et al. Stereotactic Abative body radiotherapy (SABR) for Oligometastatic prostate Cancer: a prospective clinical trial. Eur Urol. 2018;0:0. https://doi.org/10.1016/j.eururo.2018.06.004.

18. Cox BW, Spratt DE, Lovelock M, et al. International spine radiosurgery consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012;83(5):e597–603. https://doi.org/10.1016/j.ijrobp.2012.03.009.

19. Cysouw M, Bouman-Wammes E, Hoekstra O, et al. Scientific letter prognostic value of [18 F]-Fluoromethylcholine positron emission tomography/computed tomography before stereotactic body radiation therapy for Oligometastatic prostate Cancer radiation oncology. Int J Radiat Oncol Biol Phys. 2018;101(2):406–10. https://doi.org/10.1016/j.ijrobp.2018.02.005.

20. Han S, Woo S, Kim YJ, Suh CH. Impact of 68Ga-PSMA PET on the Management of Patients with prostate Cancer: a systematic review and meta-analysis. Eur Urol. 2018;74(2):179–90. https://doi.org/10.1016/j.eururo.201803.030.

21. Zacho HD, Nielsen JB, Afshar-Oromieh A, et al. Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Mol Imaging. 2018;45(11):1884–97. https://doi.org/10.1007/s00259-018-4058-4.

22. Uprimny C, Svirydenka A, Fritz J, et al. Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F] Naf PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. Eur J Nucl Mol Imaging. 2018;45(11):1873–83. https://doi.org/10.1007/s00259-018-4048-6.

23. Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS. Utility of 68Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol. 2017;61(3):372–8. https://doi.org/10.1111/1754-9485.12590.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.